<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>12</Volume>
				<Issue>6</Issue>
				<PubDate PubStatus="epublish">
					<Year>2011</Year>
					<Month>06</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Protein Expression and Significance of VEGF, EGFR and MMP-9 in Non-Small Cell Lung Carcinomas</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>1473</FirstPage>
			<LastPage>1476</LastPage>
			<ELocationID EIdType="pii">25761</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;br/&gt;&lt;b&gt;Objective&lt;/b&gt;: This study was designed to detect the protein expression of VEGF, EGFR and MMP-9, to investigate the potential roles they might play in the pathogenesis of NSCLC and to discuss their relationship and their clinical significance. &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: For 136 cases who were diagnosed of NSCLC, immunohistochemistry was used to detect protein expression of VEGF, EGFR and MMP-9 tumour and normal lung tissue specimens. Statistical analysis was performed on the relationship between protein expression of VEGF, EGFR and MMP-9 and clinico-pathological parameters and prognosis. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: Expression of VEGF and MMMP-9 was mostly in the cytoplasm, while EGFR wasfound in both cytoplasm and membranes. In NSCLCs, the positive rate of VEGF protein was 79.4% (108/136), for EGFR was 75.0% (102/136) and for MMP-9 was 68.4% (93/136), significantly greater than the normal tissue values of 16.0% (8/50), 12.0% (6/50) and 8.0% (4/50), respectively (P&lt;0.01). Expression of VEGF, EGFR and MMP-9 was related to pathology grading, lymph node metastasis and clinical staging in NSCLC (P&lt;0.01), while being independent of other clinicopathologic parameters (P&gt;0.05). There was an obvious positive correlation among the expression of VEGF and EGFR (r=0.25; P&lt;0.01), VEGF and MMP-9 (r=0.28; P&lt;0.01), EGFR and MMP-9 (r=0.19; P&lt;0.05) in NSCLCs. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: Protein expression of VEGF, EGFR and MMP-9 is elevated higher in NSCLC, correlating with progression.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">NSCLCs</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">VEGF</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">EGFR</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">MMP-9</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">immunohistochemistry</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_25761_fe34d167273a512b56145c0468f7f9d5.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
